Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11797515 | 0.83 | ALDH1A1 (0.58) | MAPTALDH1A1KDM4EMEN1THRB | |
| SCHEMBL27853710 | 0.79 | CA1 (0.60) | MAPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6613749 | 0.79 | LMNA (0.57) | MAPTALDH1A1KDM4EKMT2ATDP1 | |
| SCHEMBL9645558 | 0.79 | ALDH1A1 (0.49) | MAPTALDH1A1KDM4EMEN1THRB | |
| SCHEMBL7143263 | 0.78 | KMT2A (0.46) | MAPTALDH1A1KDM4EMEN1THRB | |
| SCHEMBL2170993 | 0.76 | LMNA (0.59) | MAPTALDH1A1KDM4EMEN1THRB | |
| SCHEMBL11841636 | 0.76 | MAPT (0.56) | MAPTALDH1A1KDM4EMEN1THRB | |
| SCHEMBL5513692 | 0.76 | TDP1 (0.58) | MAPTALDH1A1KDM4ETHRBGFER | |
| SCHEMBL5516916 | 0.76 | GAA (0.58) | MAPTALDH1A1KDM4EMEN1THRB | |
| Hydrochloric Acid SCHEMBL11841634 | 0.75 | MAPT (0.54) | MAPTALDH1A1KDM4EMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250435-B2 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050261353-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-11-24 | — | — | US | disclosed |
| EP-1417177-A4 | ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1417177-A2 | ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1414804-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048844-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-6593356-B2 | The present invention relates to the synthesis of a new class of indeno(1,2-c)pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and the | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-15 | — | — | US | disclosed |
| US-20030073686-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2003007883-A2 | ACYLSEMICARBAZIDES AS CYCLIN DEPENDENT KINASE INHIBITORS USEFUL AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002034721-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-02 | — | — | WO | disclosed |
| US-6291504-B1 | POTENT INHIBITORS OF THE CLASS OF ENZYMES KNOWN AS CYCLIN DEPENDENT KINASES | DUPONT PHARMACEUTICALS COMPANY | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073686-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CCNA1, CDK17 | MAPT 4802/4885ALDH1A1 1533/4885KDM4E 999/4885 |
| US-20050261353-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CDK17, CDK7 | MAPT 4763/4885ALDH1A1 1666/4885KDM4E 659/4885 |
| US-20040048844-A1 | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents | CDK1, CCNA1, CDK17 | MAPT 4802/4885ALDH1A1 1533/4885KDM4E 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.